Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2023; 15(5); 1912-1918

Original Research Article

Predictive Utility of Serum Ca-125 as a Biomarker in Pre-Eclampsia

Rathore Mahak¹, Mogri Sushma²

¹3rd Year PG Resident, Department of Obstetrics and Gynaecology, Geetanjali Medical College and Hospital, Udaipur
²Associate Professor, Department of Obstetrics and Gynaecology, Geetanjali Medical College and Hospital, Udaipur

Received: 13-03-2023 / Revised: 30-03-2023 / Accepted: 30-04-2023 Corresponding author: Dr Rathore Mahak Conflict of interest: Nil

Abstract

Objective: The present study aims to determine the positive predictive utility of CA-125 as a biomarker in women destined to develop pre-eclampsia.

Method: After taking proper informed consent a total of 140 singleton pregnant females at or after 20 weeks were assessed for serum CA-125 at 20 weeks and followed up to term. The patients of pre-eclampsia formed one comparison group against non-pre eclamptic group.

Result: There appears a strong co-relation between values of CA125 and incidence of preeclampsia as demonstrated by the table above and graph besides. The P value is <0.001, which is highly significant. In our study, the mean CA125 levels was 11.44 ± 4.89 IU/ml. In comparison to controls, preeclampsia patients' mean CA125 levels were considerably higher, at 49.49 ± 21.0 IU/ml (p 0.001).

Conclusion: Preeclamptic females had a mean CA-125 concentration that was substantially higher than that of normal pregnancies. A correlation between CA-125 level and the degree of pre-eclampsia was found to be positive. There exists a positive co-relation between levels of CA125, Systolic Blood Pressure, Diastolic Blood pressure, Serum uric acid and Serum Creatinine, all of which are predictors of pre-eclampsia.

Keywords: CA-125, Pre-Eclampsia, Blood Pressure, Proteinuria.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

One of the main causes of maternal and neonatal morbidity and mortality is preeclampsia. [1] According to the examined population and the clinical definitions of preeclampsia, reported rates range from 3.0 to 10%. [2,3]

The most important function of CA125, a cell-surface mucin-like coelomic antigen, in modern obstetrics and gynaecology is the early detection and monitoring of epithelial ovarian cancer.[4] However, CA125 levels

are not just indicative of ovarian cancer as values above 35 IU/ml have been observed in healthy pregnant and non-pregnant women as well as in benign gynaecological diseases. As a result, it is the subject of extensive research as a useful marker for diseases other than ovarian cancer. [5-7] There is a dearth of information regarding CA125 and its connection to preeclampsia. The purpose of the current study is to compare the levels of CA125 antigen in preeclamptic and normal pregnancies in order to ascertain whether there is any correlation between them with the condition and whether it may be utilised as a diagnostic marker.

Materials and Method

Study design: Prospective Comparative study.

Source of data: Cases included all women with singleton pregnancy who attended the antenatal visits at 20 weeks of gestation. They were assessed for CA-125 and will be followed up to term.

Study duration: From January 2021 to June 2022

Inclusion criteria

- Pregnant women attended to in antenatal clinic, labour ward and emergency unit at 20 weeks of gestation.
- 2. Singleton pregnancy without any prior knowledge of congenital anomaly or chromosomal abnormality.
- 3. Pregnant women who had given a written consent.

Exclusion criteria

- 1. Pregnant women with chronic hypertension
- 2. Pregnant women with peripheral vascular disease
- 3. Pregnant women on antihypertensive treatment
- 4. Pregnant women with kidney and heart disease
- 5. Pregnant women with coexisting TB in pregnancy, ovarian cyst and fibroids in pregnancy
- 6. Pregnant women with h/o ART, adnexal masses.

Method

A total of 140 singleton pregnant females at or after 20 weeks were assessed for CA-125 at 20 weeks and followed up to term. The patients of pre-eclampsia formed one comparison group against non-pre eclamptic group.

An informed written consent was obtained from all participants after explanation of the purpose and methodology of the research. Using a structured proforma, relevant data was obtained such as the socio-demographic characteristics, parity and estimated gestational age (EGA) was calculated based on the last menstrual periods of the participants or from early ultrasound scan done. The medical history, previous obstetric history and treatment regimens received was noted.

Pregnancy outcome was obtained by extracting information about the antenatal, labour, delivery, and new-born notes from the delivery records. Foetal outcomes such as the birth weight, intrauterine demise and special care baby unit admissions was noted.

Systolic and diastolic blood pressures measurements were taken with a standard mercury sphygmomanometer and measured to the nearest 10mmHg of mercury. The protein in urine was tested for using urine dipstick. The CA125 sample was obtained by collecting 5ml of venous blood from the participants under aseptic condition via venepuncture using a 5ml sterile disposable syringe and needle into a Lithium heparin bottle and transported from the point of collection (Labour ward, emergency room and/or lying-in ward) to the central research laboratory of the hospital where it was centrifuged for 10 minutes at 2000rpm using a refrigerated centrifuge. The resulting supernatant (i.e plasma) was transferred into clean polypropylene tubes using a Pasteur pipette in 0.5mls aliquots and stored in the freezer at a temperature of -20°C until the sample size achieved following which analysis was carried out. The CA125 levels was then assayed enzymatically with the ELISA (enzyme linked immunosorbent assay) method using reagents obtained from

the manufacturer.

Observation and Results

A total of one hundred and forty gravid women were enrolled in the forementioned study. Out of which, 70 (50%) had symptoms of preeclampsia whilst the remaining 70 (50%) were normal uncomplicated pregnancies, with respect to blood pressure, proteinuria, and biochemical tests. The mean age group of all patients in the pre-eclampsia group was 25.04 ± 4.27 years, while, the control group had a mean age of 25.31 ± 3.59 . 43% of the patients presented with as para 1 while 29% presented as nullipara. 14% patients presented with Para 2 while the rest 14% presented as multipara.

A majority of patients with pre-eclampsia were diagnosed during 33-40 weeks of gestation (61 cases; 87%). 1 case presented at <28 weeks while 2 cases presented at > 40 weeks of gestation.

A majority of patients (60%) presented as primi-gravidas, while the rest 40% presented as multi-gravidas.

| Table 1. blood 1105sure | | | | |
|-------------------------|------------------------|--------------------------|----------------|--|
| Blood Pressure | Cases Frequency | Control Frequency | <i>p</i> Value | |
| (mmHg) | (n), (%) | (n), (%) | | |
| <140/90 | | 69 (98.5%) | | |
| 140/90 to <160/110 | 43 (61.5%) | 1 (1.5%) | <0.001 | |
| >160/110 | 27 (38.5%) | | | |

Table 1: Blood Pressure

| Proteinuria (g/dL) | Cases Frequency (n), (%) | Control Frequency (n), (%) | <i>p</i> Value |
|-----------------------|-----------------------------|-------------------------------|----------------|
| 0 | | 70 (100%) | |
| +1 | | | |
| +2 | 49 (70%) | | <0.001 |
| +3 | 21 (30%) | | |





Table 2: Serum Uric Acid

| Serum Uric Acid (mg/dL) | CasesFrequency (n), (%) | Control Frequency (n), (%) | <i>p</i> Value |
|-------------------------|-------------------------|----------------------------|----------------|
| 2.0 - 4.0 | 15 (21.5%) | 61 (87%) | |
| 4.1-6.0 | 38 (54.5%) | 9 (13%) | |
| 6.1 - 8.0 | 14 (20%) | | < 0.001 |
| 8.1 - 10.0 | 3 (4%) | | |



■ 2.0 - 4.0 ■ 4.1 - 6.0 ■ 6.1 - 8.0 ■ 8.1 - 10.0

Table 3: Serum Creatinine

| Serum Creatinine | Cases | Control | <i>p</i> Value |
|------------------|--------------------|--------------------|----------------|
| (mg/dL) | Frequency (n), (%) | Frequency (n), (%) | |
| < 1.1 | 22 (31.5%) | 50 (71.5%) | |
| 1.1 – 2.9 | 43 (61.5%) | 20 (28.5%) | |
| > 3.0 | 5 (7%) | | 0.039 |



| Table 4: CA 125 | | | | |
|------------------------|---------------|---------------|------------------|----------------|
| Group | Lowest CA125 | Highest CA125 | Mean Serum | <i>p</i> Value |
| | Level (IU/mL) | Level (IU/mL) | CA125 (IU/mL) | |
| Pre-eclampsia | 12.45 | 84.72 | 49.49 ± 21.0 | |
| group (Cases) | | | | < 0.0001 |
| Control | 1.50 | 19.28 | 11.44 ± 4.89 | |

| Difference | 38.050 |
|--------------------|--------------------|
| Standard error | 2.577 |
| 95% CI | 43.1458 to 32.9542 |
| t-statistic | 14.764 |
| DF | 138 |
| Significance level | P < 0.0001 |

There appears a strong co-relation between values of CA125 and incidence of pre-eclampsia as demonstrated by the table above and graph besides. The P value is <0.001, which is highly significant.



Pearson's linear co-efficient of correlation between CA125 and Clinico-laboratory parameters of patients with pre-eclampsia and controls:

| Parameters | Pearson's Co-efficient of Correlation (r) | р |
|---------------|---|---------|
| Systolic BP | 0.350 | < 0.001 |
| Diastolic BP | 0.339 | < 0.001 |
| Proteinuria | 0.320 | 0.002 |
| S. Creatinine | 0.335 | 0.001 |
| S. Uric Acid | 0.103 | 0.001 |

Discussion

Out of 140 patients that included in the study, the mean age group of all patients The mean age group of all patients in the pre-eclampsia group was 25.04 ± 4.27 years, while, the control group had a mean age of 25.31 ± 3.59 .

In a study conducted by Rekha Reddy et. al. [8] conducted a study with 100 preeclamptic women. The mean age of the patients was 26.46 years.

In a study conducted by Villar *et al.* [9] 11% of all first pregnancies (or 5% of all pregnancies overall) are complicated by hypertension. About half of these are brought on by or connected with pre-eclampsia.

In comparison to the cases' parity and gestational the controls age, were normotensive females. In our study, the mean CA125 levels was 11.44 ± 4.89 IU/ml. This data supports the findings of the Niloff et. al. [8] study, which showed that in healthy, uncomplicated pregnancies, CA125 levels are increased in the first trimester, decline, and remain below 35IU/ml throughout the remainder of the pregnancy, including just before delivery. [12,15] The CA125 levels of the controls in the Cebesoy and Karaman studies [10,11] were also low, at 14.64 IU/ml and 17.2 IU/ml, respectively.

In comparison to controls, preeclampsia patients' mean CA125 levels were considerably higher, at 49.49 ± 21.0 IU/ml (p 0.001). Similar studies have been conducted by Mustafa *et al.* [12], Cebesoy *et al.* [10], and Karaman *et al.* [11], all of which found that CA125 is raised in preeclampsia, and more specifically, severe preeclampsia. The

average blood CA125 concentration in the Mustafa *et al.* study was 55.70 ± 8.72 IU/ml for men and 59.11 ± 4.28 IU/ml for women.

Conclusion

According to this study, preeclamptic females had a mean CA-125 concentration that was substantially higher than that of normal pregnancies. Additionally, a correlation between the CA-125 level and the degree of preeclampsia was found to be positive. Clarification of the clinical applicability of CA-125 as a preeclampsia prediction requires more study.

There exists a positive co-relation between levels of CA125, Systolic Blood Pressure, Diastolic Blood pressure, Serum Uric acid and Serum Creatinine, all of which are predictors of pre-eclampsia.

Further research needs to be done in order to co-relate the grade of pre-eclampsia with the aforementioned parameters with a larger study population.

References

- 1. De Swiet, Michael. Medical Disorders in Obstetrical Practice. 4th Edition, 2002.
- Magee L. A., Helewa M., Moutquin J.-M., von Dadelszen P. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. Journal of Obstetrics and Gynaecology Canada. 2008; 30; 3.
- Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet. 2001; 357; 209-215.

- Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P *et al.* Prognostic value of repeated serum CA125 measurements in first trimester of pregnancy. Eur J Obstet Gyneacol reprod Biol. 2001; 97:168-173.
- 5. O'Brien TJ, Hardin JW, Bannon GA, Norris JG, Quirk Jnr JG. CA125 antigen in human amniotic fluid and fetal membranes. AJOG. 1986; 155;50-55.
- M. A. Osmanagaoglu M A, Erdogan I, Eminagaoglu S, Karahan S C, S Ozgu, G Can, Bozkaya H. The diagnostic value of b-human chorionic gonadotropin, progesterone, Ca125 in the prediction of abortions. J Obstet Gynecol. 2010; 30(3): 288-293.
- Witt BR, Wolf GC, Wainwright BJ, Johnston PD, Thorneyccoft IH. Relaxin, CA125 measurements in first trimester of pregnancy. Eur J Obstet Gyneacol reprod Biol. 2001; 97:168-173.
- 8. Rekha Reddy, Sireesha, Manjula, Shruthi Manivikar: Significance of spot urine protein creatinine ratio versus 24-hour

urinary protein analysis and their correlation in quantification of proteinuria in hypertensive pregnant women – A Prospective Observational Study; 2015.

- 9. Sibai BM, Barton JR: Expectant management of severe preeclampsia remote from term: patient selection treatment and delivery indication. Am J Obstet Gynacol. 2007; 196:514-516.
- Cebesoy F B, Ozcan B, Ebru D, Hakan K, Yelda I. CA125 and CRP are Elevated in Preeclampsia. Hypertens Pregnancy. 2009; 28(2): 201-211.
- 11. Karaman E, Karaman Y, Alkis I, Han A, Yildrim G, Ark HC.Maternal serum CA125 level is elevated in severe preeclampsia. Preg Hyper: An Int J Women's Card health. 2013.
- Mustafa O, Kanat-Pektas M, Okan Y, Tayfun G, Nuri D and Mollamahmutoglu L. Serum concentrations of CA125 in normal and preeclamptic pregnancies. Arch Gynecol Obstet. 2010; 284(3): 607-612.